156 related articles for article (PubMed ID: 3102087)
1. Recent experience with ifosfamide/mesna in solid tumors. International satellite symposium to the 3rd European Conference on Clinical Oncology. Stockholm, June 1985. Proceedings.
Cancer Chemother Pharmacol; 1986; 18 Suppl 2():S1-58. PubMed ID: 3102087
[No Abstract] [Full Text] [Related]
2. Proceedings of a symposium on ifosfamide (Mitoxana; Holoxan) and Mesna (Uromitexan). Coventry, U.K., 16-18 March 1983.
Cancer Treat Rev; 1983 Sep; 10 Suppl A():1-192. PubMed ID: 6414687
[No Abstract] [Full Text] [Related]
3. Ifosfamide and Mesna in advanced malignancies.
Li GC; Brock N; Li JQ; Guan ZZ; He YJ
Chin Med J (Engl); 1988 Mar; 101(3):213-20. PubMed ID: 3136996
[No Abstract] [Full Text] [Related]
4. Ifosfamide and mesna.
Schoenike SE; Dana WJ
Clin Pharm; 1990 Mar; 9(3):179-91. PubMed ID: 2107997
[TBL] [Abstract][Full Text] [Related]
5. Phase II trial of ifosfamide/mesna in metastatic adult renal carcinoma.
De Forges A; Droz JP; Ghosn M; Theodore C
Cancer Treat Rep; 1987 Nov; 71(11):1103. PubMed ID: 3119203
[No Abstract] [Full Text] [Related]
6. Nursing implications in the administration of ifosfamide and mesna.
Richters JE
Oncol Nurs Forum; 1990; 17(2):276. PubMed ID: 2107534
[No Abstract] [Full Text] [Related]
7. False-positive ketonuria during ifosfamide and mesna therapy.
Cantwell BM; Pooley J; Harris AL
Eur J Cancer Clin Oncol; 1986 Feb; 22(2):229-30. PubMed ID: 3084264
[No Abstract] [Full Text] [Related]
8. Ifosfamide in gynecological tumors. Satellite symposium of 5th European Conference on Clinical Oncology and Cancer Nursing. London, September 3-7, 1989. Proceedings.
Cancer Chemother Pharmacol; 1990; 26 Suppl():S1-102. PubMed ID: 2347044
[No Abstract] [Full Text] [Related]
9. Malignant pleural mesothelioma: phase II pilot study of ifosfamide and mesna.
Alberts AS; Falkson G; Van Zyl L
J Natl Cancer Inst; 1988 Jul; 80(9):698-700. PubMed ID: 3131539
[No Abstract] [Full Text] [Related]
10. [Clinical evaluation of Mitexan in the prevention of urinary tract complications during treatment with Holoxan].
Czownicki Z; Utracka-Hutka B
Nowotwory; 1981; 30(4):377-83. PubMed ID: 6792599
[No Abstract] [Full Text] [Related]
11. Response of pediatric malignant solid tumors following ifosfamide or ifosfamide/carboplatin/etoposide: a single hospital experience.
Pratt CB; Luo X; Fang L; Marina N; Avery L; Furman WL
Med Pediatr Oncol; 1996 Sep; 27(3):145-8. PubMed ID: 8699990
[TBL] [Abstract][Full Text] [Related]
12. Fatal encephalopathy with ifosfamide/mesna.
Verdeguer A; Castel V; Esquembre C; Ferris J; Fernandez JM; Ruiz JG
Pediatr Hematol Oncol; 1989; 6(4):383-5. PubMed ID: 2518327
[No Abstract] [Full Text] [Related]
13. Clinical overview of mesna.
Burkert H
Cancer Treat Rev; 1983 Sep; 10 Suppl A():175-81. PubMed ID: 6414692
[TBL] [Abstract][Full Text] [Related]
14. Ifosfamide with mesna uroprotection in the management of lung cancer.
Holoye PY; Glisson BS; Lee JS; Dhingra HM; Murphy WK; Umsawasdi T; Levy JK; Jeffries D; Raber MN; Hong WK
Am J Clin Oncol; 1990 Apr; 13(2):148-55. PubMed ID: 2156418
[TBL] [Abstract][Full Text] [Related]
15. Treatment of metastatic renal cancer with ifosfamide and mesnum with and without irradiation.
Fosså SD; Talle K
Cancer Treat Rep; 1980; 64(10-11):1103-8. PubMed ID: 6780190
[TBL] [Abstract][Full Text] [Related]
16. Current developments and future direction with ifosfamide. Proceedings of a satellite symposium of the European Society of Medical Oncology. October 31, 1988, Lugano, Switzerland.
Semin Oncol; 1989 Feb; 16(1 Suppl 3):1-101. PubMed ID: 2704999
[No Abstract] [Full Text] [Related]
17. Paraplatin (carboplatin). Current status and future prospects. Proceedings of a satellite symposium held at Stockholm, Sweden, 19th June 1985, during the 3rd European Conference on Clinical Oncology.
Cancer Treat Rev; 1985 Sep; 12 Suppl A():1-152. PubMed ID: 3910214
[No Abstract] [Full Text] [Related]
18. Mesnum as a protector against kidney and bladder toxicity with high-dose ifosfamide treatment.
Falkson G; Van Dyk JJ; Stapelberg R; Falkson HC
Cancer Chemother Pharmacol; 1982; 9(2):81-4. PubMed ID: 6816479
[TBL] [Abstract][Full Text] [Related]
19. Failure of 2-mercaptoethane sulphonate sodium (mesna) to protect against ifosfamide nephrotoxicity.
Sangster G; Kaye SB; Calman KC; Dalton JF
Eur J Cancer Clin Oncol; 1984 Mar; 20(3):435-6. PubMed ID: 6423391
[No Abstract] [Full Text] [Related]
20. Ifosfamide in the treatment of pediatric malignancies. 4th European Conference on Clinical Oncology and Cancer Nursing. Madrid, November 1987. Proceedings.
Cancer Chemother Pharmacol; 1989; 24 Suppl 1():S1-51. PubMed ID: 2758565
[No Abstract] [Full Text] [Related]
[Next] [New Search]
